Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations Xavier CahuStefan N. Constantinescu Myeloproliferative Disorders (C Harrison, Section Editor) 14 September 2015 Pages: 335 - 343
Current Challenges in Stem Cell Transplantation in Myelofibrosis Nicolaus Kröger Myeloproliferative Disorders (C Harrison, Section Editor) 19 August 2015 Pages: 344 - 350
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis Jason Gotlib Myeloproliferative Disorders (C Harrison, Section Editor) 24 September 2015 Pages: 351 - 361
Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis Giovanni Barosi Myeloproliferative Disorders (C Harrison, Section Editor) 16 August 2015 Pages: 362 - 369
Immunological Consequences of JAK Inhibition: Friend or Foe? Donal P. McLornanAlesia A. KhanClaire N. Harrison Myeloproliferative Disorders (C Harrison, Section Editor) 21 August 2015 Pages: 370 - 379
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice? Paola GuglielmelliGiada RotunnoAlessandro Maria Vannucchi Myeloproliferative Disorders (C Harrison, Section Editor) 02 October 2015 Pages: 380 - 387
Novel Induction Regimens in Multiple Myeloma Karie D. RuncieTomer M. Mark Multiple Myeloma (R Nievszky, Section Editor) 15 August 2015 Pages: 388 - 394
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies Rebecca Karp LeafHearn Jay ChoDavid Avigan Multiple Myeloma (R Nievszky, Section Editor) 04 September 2015 Pages: 395 - 404
Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider Michael A. ThompsonNavneet S. MajhailMélanie Chaboissier Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 09 October 2015 Pages: 405 - 412
Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM Naveen PemmarajuVikas GuptaMichael A. Thompson Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 28 September 2015 Pages: 413 - 420
Mature T-cell leukemias: Molecular and Clinical Aspects Nathanael G. BaileyKojo S. J. Elenitoba-Johnson T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 03 October 2015 Pages: 421 - 428
Molecular Pathogenesis of Peripheral T Cell Lymphoma Mamiko Sakata-YanagimotoShigeru Chiba T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 02 October 2015 Pages: 429 - 437
Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas Jonathan HebbHolbrook Kohrt T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 03 October 2015 Pages: 438 - 447
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project Monica BelleiChadi NabhanMassimo Federico T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 08 October 2015 Pages: 448 - 455
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment A. A. GruB. H. HaverkosP. Porcu T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 08 October 2015 Pages: 456 - 467
Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy Catherine G. ChungBrian Poligone T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor) 01 December 2015 Pages: 468 - 476
